Advaxis Inc. (ADXS) Trading Up 3.7%
Advaxis Inc. (NASDAQ:ADXS) shares traded up 3.7% during mid-day trading on Wednesday . The company traded as high as $8.41 and last traded at $8.33, with a volume of 221,906 shares changing hands. The stock had previously closed at $8.03.
A number of research analysts have issued reports on the stock. Jefferies Group reaffirmed a “buy” rating on shares of Advaxis in a report on Friday, June 10th. HC Wainwright reaffirmed a “buy” rating on shares of Advaxis in a report on Wednesday, June 29th. Finally, FBR & Co reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Advaxis in a report on Thursday, July 7th. Six analysts have rated the stock with a buy rating, Advaxis has an average rating of “Buy” and an average target price of $24.80.
The firm’s market cap is $286.45 million. The company’s 50 day moving average is $8.23 and its 200-day moving average is $7.97.
In other news, CEO Daniel O’connor sold 8,237 shares of Advaxis stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $7.51, for a total value of $61,859.87. Following the completion of the transaction, the chief executive officer now directly owns 316,661 shares of the company’s stock, valued at approximately $2,378,124.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Thomas J. Mckearn sold 4,100 shares of Advaxis stock in a transaction dated Friday, May 13th. The shares were sold at an average price of $7.45, for a total transaction of $30,545.00. Following the completion of the transaction, the director now directly owns 82,120 shares of the company’s stock, valued at $611,794. The disclosure for this sale can be found here.
Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.